Endpoints News

FDA approves Replimune melanoma drug previously rejected twice

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

AstraZeneca-Bristol Myers: Brace for a Biotech M&A Boom

Novo outlook hike falls flat as Wegovy pill sales fail to impress

AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up

Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson has proposed a $5.5 billion settlement to resolve ongoing legal challenges involving its talc-based baby powder products.

Argenx to Buy Forte Biosciences for $2.2 Billion

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

The Great Peptide Cash Grab Has Begun

An FDA advisory panel review of seven peptides is sparking a debate over longevity medicine, public health risks, and potential multibillion-dollar markets.

Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia

Bristol Myers Squibb is partnering with Nvidia to build what it describes as the most powerful AI supercomputer in the life sciences industry.

The F.D.A. Approves a New Pill to Slash Cholesterol Levels

The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.

FDA releases 14 drug rejection letters after 3-month pause

FDA resumes releasing drug rejection letters after 3-month pause

The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy

An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from initial human trials.

'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Compass says depression drug has long-lasting benefits

Compass Pathways reports positive six-month data for its psilocybin-based depression treatment, fueling market confidence and future filing plans.

Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback

Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.

Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles

Vertex Pharmaceuticals is expanding into endocrine disease drugs through a $10 billion acquisition of Crinetics.

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs

Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs

Revolution Medicines shares promising data around KRAS drug combination

Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.

Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial

Roche's drug candidate divarasib outperformed rival therapies in a Phase 3 trial for KRAS-driven lung cancer.

FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports

Anthropic releases Claude Science, a product aimed at researchers, the pharma industry

Anthropic has entered the scientific research and pharmaceutical sectors with the launch of its new AI workbench, Claude Science.

FDA’s top gene therapy regulator is leaving his role

EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials

A US House committee has launched an investigation into drug trials conducted in China by major pharmaceutical companies, including Merck and AbbVie.

French biotech stock soars 34% after new data on experimental medicine

Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion

French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.

New Drugs Are Replacing Chemo for Aggressive Breast Cancer

The FDA has granted broad first-line approval for Gilead's Trodelvy, signaling a shift away from traditional chemotherapy for aggressive breast cancer.

Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing

Ophthalmology venture grabs investors’ attention, raises $330 million

Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial

AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion